Abstract 2143
Background
Patients (pts) who underwent a curative resection for solitary colorectal liver metastasis (CRLM) have a relatively favorable prognosis. Clinical impact of BRAF V600E mutations in those pts remains unclear.
Methods
Consecutive pts who had undergone initial hepatectomy for histologically confirmed solitary CRLM were included. Tumor RAS (KRAS/NRAS)/BRAF V600E mutation tests were centrally performed by a PCR method. The association between BRAF V600E mutation and survival outcome in pts with resectable solitary CRLM was retrospectively investigated.
Results
From Jan 2005 to Dec 2017, 218 pts were included with a median follow-up of 52 months (m). BRAF mutant (mBRAF) was observed in 5 (2.3%) pts, while mRAS was in 92 (42.2%) pts and RAS/BRAF wild-type (wRAS/BRAF) was in 121 (55.5%) pts. mBRAF was associated with a higher serum CA19-9 level at pre-hepatectomy (p = 0.03). Median longest diameter for solitary CRLM were similar among three cohorts (19 mm vs. 25 mm vs. 27 mm, p = 0.21). However, all the mBRAF pts experienced early recurrence within 9 m. In the univariate analysis, mBRAF was associated with a worse survival in terms of both recurrence-free survival (RFS) with the hazard ratio (HR) of 8.68 for mBRAF vs. wRAS/BRAF (mBRAF vs. mRAS vs. wRAS/BRAF; median, 4.8 m vs. 17.1 m vs. not reached, p < 0.001: 3-year RFS rate, 0% vs 39.6% vs 56.2%, p < 0.001) and overall survival (OS) with the HR of 20.8 for mBRAF vs. wRAS/BRAF (mBRAF vs. mRAS vs. wRAS/BRAF; median, 14.4 m vs. not reached vs. not reached, p < 0.001: 3-year OS rate, 20.0% vs 78.9% vs 94.9%, p < 0.001). In the multivariate analysis, mBRAF was strongly associated with a worse survival and had the highest HR among all the indicators in terms of both RFS (HR: 5.0, 95% CI: 1.8–13.8, p < 0.001) and OS (HR: 15.4, 95% CI: 5.2–45.5, p < 0.001).
Conclusions
Among resectable solitary CRLM pts, mBRAF was rare (2.3%). However, given that all the mBRAF pts experienced early recurrence and the striking value of HRs in the univariate and multivariate analyses on both RFS and OS, mBRAF itself may become the most relevant indicator beyond known clinicopathological indicators in pts with resectable solitary CRLM. A novel treatment strategy for these patients is warranted.
Clinical trial identification
UMIN000034557.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Cancer Center Research Development Fund, Japan (Research number: 30-A-8, Principal investigator: Shinichiro Takahashi).
Disclosure
T. Yoshino: Research grant / Funding (self): Novartis Pharma K.K.; Research grant / Funding (self): MSD.K.K.; Research grant / Funding (self): Sumitomo Dainippon Pharma Co., Ltd.; Research grant / Funding (self): Chugai Pharmaceutical Co., Ltd.; Research grant / Funding (self): Sanofi K.K.; Research grant / Funding (self): Daiichi Sankyo Company, Limited; Research grant / Funding (self): PAREXEL International Inc.; Research grant / Funding (self): Ono Pharmaceutical Co., Ltd. H. Taniguchi: Research grant / Funding (self): Takeda; Research grant / Funding (self): Daiichi Sankyo; Research grant / Funding (self): Sysmex; Honoraria (self): Chugai; Honoraria (self): Taiho; Honoraria (self): Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract